BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HP, Remuzzi G, Zipfel PF. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest. 2003;111:1181-1190. [PMID: 12697737 DOI: 10.1172/jci16651] [Cited by in Crossref: 217] [Cited by in F6Publishing: 113] [Article Influence: 11.4] [Reference Citation Analysis]
Number Citing Articles
1 Schmidt CQ, Herbert AP, Hocking HG, Uhrín D, Barlow PN. Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol. 2008;151:14-24. [PMID: 18081691 DOI: 10.1111/j.1365-2249.2007.03553.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 7.2] [Reference Citation Analysis]
2 Leffler J, Herbert AP, Norström E, Schmidt CQ, Barlow PN, Blom AM, Martin M. Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. J Biol Chem. 2010;285:3766-3776. [PMID: 19951950 DOI: 10.1074/jbc.m109.045427] [Cited by in Crossref: 47] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
3 Jokiranta TS, Jaakola VP, Lehtinen MJ, Pärepalo M, Meri S, Goldman A. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J 2006;25:1784-94. [PMID: 16601698 DOI: 10.1038/sj.emboj.7601052] [Cited by in Crossref: 126] [Cited by in F6Publishing: 118] [Article Influence: 7.9] [Reference Citation Analysis]
4 Harris CL, Heurich M, Rodriguez de Cordoba S, Morgan BP. The complotype: dictating risk for inflammation and infection. Trends Immunol. 2012;33:513-521. [PMID: 22749446 DOI: 10.1016/j.it.2012.06.001] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 9.3] [Reference Citation Analysis]
5 Miyake M, Saito M, Yamashiro K, Sekiryu T, Yoshimura N. Complement factor H R1210C among Japanese patients with age-related macular degeneration. Jpn J Ophthalmol 2015;59:273-8. [PMID: 26215151 DOI: 10.1007/s10384-015-0394-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
6 Pechtl IC, Kavanagh D, McIntosh N, Harris CL, Barlow PN. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem 2011;286:11082-90. [PMID: 21270465 DOI: 10.1074/jbc.M110.211839] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
7 Fujisawa M, Kato H, Yoshida Y, Usui T, Takata M, Fujimoto M, Wada H, Uchida Y, Kokame K, Matsumoto M, Fujimura Y, Miyata T, Nangaku M. Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol 2018;22:1088-99. [PMID: 29511899 DOI: 10.1007/s10157-018-1549-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
8 Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012;8:622-33. [PMID: 22986360 DOI: 10.1038/nrneph.2012.195] [Cited by in Crossref: 247] [Cited by in F6Publishing: 218] [Article Influence: 24.7] [Reference Citation Analysis]
9 Harboe M, Mollnes TE. The alternative complement pathway revisited. J Cell Mol Med 2008;12:1074-84. [PMID: 18419792 DOI: 10.1111/j.1582-4934.2008.00350.x] [Cited by in Crossref: 178] [Cited by in F6Publishing: 164] [Article Influence: 12.7] [Reference Citation Analysis]
10 Manea M, Kristoffersson A, Tsai HM, Zhou W, Winqvist I, Oldaeus G, Billström R, Björk P, Holmberg L, Karpman D. ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr 2007;166:249-57. [PMID: 17187257 DOI: 10.1007/s00431-006-0354-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
11 Tortajada A, Yébenes H, Abarrategui-Garrido C, Anter J, García-Fernández JM, Martínez-Barricarte R, Alba-Domínguez M, Malik TH, Bedoya R, Cabrera Pérez R. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest. 2013;123:2434-2446. [PMID: 23728178 DOI: 10.1172/jci68280] [Cited by in Crossref: 140] [Cited by in F6Publishing: 82] [Article Influence: 15.6] [Reference Citation Analysis]
12 den Hollander AI, de Jong EK. Highly penetrant alleles in age-related macular degeneration. Cold Spring Harb Perspect Med 2014;5:a017202. [PMID: 25377141 DOI: 10.1101/cshperspect.a017202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
13 Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005;201:871-9. [PMID: 15781579 DOI: 10.1084/jem.20041497] [Cited by in Crossref: 252] [Cited by in F6Publishing: 235] [Article Influence: 14.8] [Reference Citation Analysis]
14 Lehtinen MJ, Rops AL, Isenman DE, van der Vlag J, Jokiranta TS. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem 2009;284:15650-8. [PMID: 19351878 DOI: 10.1074/jbc.M900814200] [Cited by in Crossref: 74] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
15 Bhattacharjee A, Reuter S, Trojnár E, Kolodziejczyk R, Seeberger H, Hyvärinen S, Uzonyi B, Szilágyi Á, Prohászka Z, Goldman A, Józsi M, Jokiranta TS. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease. J Biol Chem 2015;290:9500-10. [PMID: 25659429 DOI: 10.1074/jbc.M114.630871] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
16 Michelfelder S, Parsons J, Bohlender LL, Hoernstein SNW, Niederkrüger H, Busch A, Krieghoff N, Koch J, Fode B, Schaaf A, Frischmuth T, Pohl M, Zipfel PF, Reski R, Decker EL, Häffner K. Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders. J Am Soc Nephrol 2017;28:1462-74. [PMID: 27932477 DOI: 10.1681/ASN.2015070745] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
17 Agarwal V, Asmat TM, Luo S, Jensch I, Zipfel PF, Hammerschmidt S. Complement regulator Factor H mediates a two-step uptake of Streptococcus pneumoniae by human cells. J Biol Chem 2010;285:23486-95. [PMID: 20504767 DOI: 10.1074/jbc.M110.142703] [Cited by in Crossref: 63] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
18 Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Müslümanoğlu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003;100:12966-71. [PMID: 14566051 DOI: 10.1073/pnas.2135497100] [Cited by in Crossref: 310] [Cited by in F6Publishing: 269] [Article Influence: 16.3] [Reference Citation Analysis]
19 Shaughnessy J, Gulati S, Agarwal S, Unemo M, Ohnishi M, Su XH, Monks BG, Visintin A, Madico G, Lewis LA, Golenbock DT, Reed GW, Rice PA, Ram S. A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol 2016;196:1732-40. [PMID: 26773149 DOI: 10.4049/jimmunol.1500292] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
20 Zipfel PF, Edey M, Heinen S, Józsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007;3:e41. [PMID: 17367211 DOI: 10.1371/journal.pgen.0030041] [Cited by in Crossref: 233] [Cited by in F6Publishing: 221] [Article Influence: 15.5] [Reference Citation Analysis]
21 Clark SJ, Ridge LA, Herbert AP, Hakobyan S, Mulloy B, Lennon R, Würzner R, Morgan BP, Uhrín D, Bishop PN, Day AJ. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J Immunol 2013;190:2049-57. [PMID: 23365078 DOI: 10.4049/jimmunol.1201751] [Cited by in Crossref: 94] [Cited by in F6Publishing: 93] [Article Influence: 10.4] [Reference Citation Analysis]
22 Ostrycharz E, Hukowska-szematowicz B. New Insights into the Role of the Complement System in Human Viral Diseases. Biomolecules 2022;12:226. [DOI: 10.3390/biom12020226] [Reference Citation Analysis]
23 de Jorge EG, Macor P, Paixão-Cavalcante D, Rose KL, Tedesco F, Cook HT, Botto M, Pickering MC. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 2011;22:137-45. [PMID: 21148255 DOI: 10.1681/ASN.2010050451] [Cited by in Crossref: 85] [Cited by in F6Publishing: 36] [Article Influence: 7.1] [Reference Citation Analysis]
24 Smith RJ, Harris CL, Pickering MC. Dense deposit disease. Mol Immunol. 2011;48:1604-1610. [PMID: 21601923 DOI: 10.1016/j.molimm.2011.04.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
25 Poppelaars F, Goicoechea de Jorge E, Jongerius I, Baeumner AJ, Steiner MS, Józsi M, Toonen EJM, Pauly D; SciFiMed consortium. A Family Affair: Addressing the Challenges of Factor H and the Related Proteins. Front Immunol 2021;12:660194. [PMID: 33868311 DOI: 10.3389/fimmu.2021.660194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Duvvari MR, Paun CC, Buitendijk GH, Saksens NT, Volokhina EB, Ristau T, Schoenmaker-Koller FE, van de Ven JP, Groenewoud JM, van den Heuvel LP, Hofman A, Fauser S, Uitterlinden AG, Klaver CC, Hoyng CB, de Jong EK, den Hollander AI. Analysis of rare variants in the C3 gene in patients with age-related macular degeneration. PLoS One 2014;9:e94165. [PMID: 24736606 DOI: 10.1371/journal.pone.0094165] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
27 Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol. 2015;6:262. [PMID: 26082779 DOI: 10.3389/fimmu.2015.00262] [Cited by in Crossref: 521] [Cited by in F6Publishing: 553] [Article Influence: 74.4] [Reference Citation Analysis]
28 Borza DB. Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation. Matrix Biol. 2017;57-58:299-310. [PMID: 27609404 DOI: 10.1016/j.matbio.2016.09.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
29 Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, Cayla M, Tabarin F, Jablonski M, Hue C. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol. 2014;25:2053-2065. [PMID: 24652797 DOI: 10.1681/asn.2013070796] [Cited by in Crossref: 68] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
30 Friese MA, Manuelian T, Junnikkala S, Hellwage J, Meri S, Peter HH, Gordon DL, Eibel H, Zipfel PF. Release of endogenous anti-inflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis. Clin Exp Immunol 2003;132:485-95. [PMID: 12780697 DOI: 10.1046/j.1365-2249.2003.02173.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
31 Meri T, Blom AM, Hartmann A, Lenk D, Meri S, Zipfel PF. The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein. Infect Immun 2004;72:6633-41. [PMID: 15501796 DOI: 10.1128/IAI.72.11.6633-6641.2004] [Cited by in Crossref: 96] [Cited by in F6Publishing: 48] [Article Influence: 5.3] [Reference Citation Analysis]
32 Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008;23:1957-72. [PMID: 18594873 DOI: 10.1007/s00467-008-0872-4] [Cited by in Crossref: 135] [Cited by in F6Publishing: 109] [Article Influence: 9.6] [Reference Citation Analysis]
33 Recalde S, Tortajada A, Subias M, Anter J, Blasco M, Maranta R, Coco R, Pinto S, Noris M, García-Layana A, Rodríguez de Córdoba S. Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. J Am Soc Nephrol 2016;27:1305-11. [PMID: 26376859 DOI: 10.1681/ASN.2015050580] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
34 Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement Dysregulation and Disease: Insights from Contemporary Genetics. Annu Rev Pathol. 2017;12:25-52. [PMID: 27959629 DOI: 10.1146/annurev-pathol-012615-044145] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
35 Kopp A, Hebecker M, Svobodová E, Józsi M. Factor h: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules 2012;2:46-75. [PMID: 24970127 DOI: 10.3390/biom2010046] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 7.2] [Reference Citation Analysis]
36 Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. Front Immunol 2019;10:853. [PMID: 31118930 DOI: 10.3389/fimmu.2019.00853] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
37 Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med. 2007;204:1249-1256. [PMID: 17517971 DOI: 10.1084/jem.20070301] [Cited by in Crossref: 201] [Cited by in F6Publishing: 180] [Article Influence: 13.4] [Reference Citation Analysis]
38 Loeven MA, Rops AL, Lehtinen MJ, van Kuppevelt TH, Daha MR, Smith RJ, Bakker M, Berden JH, Rabelink TJ, Jokiranta TS, van der Vlag J. Mutations in Complement Factor H Impair Alternative Pathway Regulation on Mouse Glomerular Endothelial Cells in Vitro. J Biol Chem 2016;291:4974-81. [PMID: 26728463 DOI: 10.1074/jbc.M115.702506] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
39 Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P, Noël LH, Fakhouri F. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007;44:193-9. [PMID: 17018561 DOI: 10.1136/jmg.2006.045328] [Cited by in Crossref: 211] [Cited by in F6Publishing: 187] [Article Influence: 13.2] [Reference Citation Analysis]
40 Clark SJ, Bishop PN. Role of Factor H and Related Proteins in Regulating Complement Activation in the Macula, and Relevance to Age-Related Macular Degeneration. J Clin Med 2015;4:18-31. [PMID: 25729613 DOI: 10.3390/jcm4010018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
41 Menon MC, Chuang PY, He CJ. The glomerular filtration barrier: components and crosstalk. Int J Nephrol 2012;2012:749010. [PMID: 22934182 DOI: 10.1155/2012/749010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Jokiranta TS, Cheng ZZ, Seeberger H, Jòzsi M, Heinen S, Noris M, Remuzzi G, Ormsby R, Gordon DL, Meri S, Hellwage J, Zipfel PF. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol 2005;167:1173-81. [PMID: 16192651 DOI: 10.1016/S0002-9440(10)61205-9] [Cited by in Crossref: 93] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
43 Pickering MC, Cook HT. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008;151:210-30. [PMID: 18190458 DOI: 10.1111/j.1365-2249.2007.03574.x] [Cited by in Crossref: 130] [Cited by in F6Publishing: 111] [Article Influence: 9.3] [Reference Citation Analysis]
44 Yu Y, Triebwasser MP, Wong EK, Schramm EC, Thomas B, Reynolds R, Mardis ER, Atkinson JP, Daly M, Raychaudhuri S, Kavanagh D, Seddon JM. Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration. Hum Mol Genet 2014;23:5283-93. [PMID: 24847005 DOI: 10.1093/hmg/ddu226] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 8.0] [Reference Citation Analysis]
45 Borza DB. Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy. Front Immunol 2016;7:157. [PMID: 27199983 DOI: 10.3389/fimmu.2016.00157] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
46 Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF, Silvestri G, Skerka C, Józsi M, Zipfel PF, Hageman GS, Smith RJ. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006;43:582-9. [PMID: 16299065 DOI: 10.1136/jmg.2005.038315] [Cited by in Crossref: 160] [Cited by in F6Publishing: 146] [Article Influence: 9.4] [Reference Citation Analysis]
47 Józsi M, Oppermann M, Lambris JD, Zipfel PF. The C-terminus of complement factor H is essential for host cell protection. Mol Immunol 2007;44:2697-706. [PMID: 17208302 DOI: 10.1016/j.molimm.2006.12.001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 4.9] [Reference Citation Analysis]
48 Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007;171:715-727. [PMID: 17640961 DOI: 10.2353/ajpath.2007.070166] [Cited by in Crossref: 396] [Cited by in F6Publishing: 359] [Article Influence: 26.4] [Reference Citation Analysis]
49 Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010;25:2431-42. [PMID: 20526633 DOI: 10.1007/s00467-010-1555-5] [Cited by in Crossref: 117] [Cited by in F6Publishing: 98] [Article Influence: 9.8] [Reference Citation Analysis]
50 Castelletti F, Donadelli R, Banterla F, Hildebrandt F, Zipfel PF, Bresin E, Otto E, Skerka C, Renieri A, Todeschini M, Caprioli J, Caruso RM, Artuso R, Remuzzi G, Noris M. Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci U S A 2008;105:2538-43. [PMID: 18268355 DOI: 10.1073/pnas.0707730105] [Cited by in Crossref: 83] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
51 Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33:479-492. [PMID: 24161035 DOI: 10.1016/j.semnephrol.2013.08.001] [Cited by in Crossref: 350] [Cited by in F6Publishing: 309] [Article Influence: 43.8] [Reference Citation Analysis]
52 Sakaue T, Takeuchi K, Maeda T, Yamamoto Y, Nishi K, Ohkubo I. Factor H in porcine seminal plasma protects sperm against complement attack in genital tracts. J Biol Chem 2010;285:2184-92. [PMID: 19920146 DOI: 10.1074/jbc.M109.063495] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
53 Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP. Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol 2009;183:3150-9. [PMID: 19667083 DOI: 10.4049/jimmunol.0901366] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
54 Ueda Y, Mohammed I, Song D, Gullipalli D, Zhou L, Sato S, Wang Y, Gupta S, Cheng Z, Wang H, Bao J, Mao Y, Brass L, Zheng XL, Miwa T, Palmer M, Dunaief J, Song WC. Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation. Blood 2017;129:1184-96. [PMID: 28057640 DOI: 10.1182/blood-2016-07-728253] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
55 Gyapon-Quast F, Goicoechea de Jorge E, Malik T, Wu N, Yu J, Chai W, Feizi T, Liu Y, Pickering MC. Defining the Glycosaminoglycan Interactions of Complement Factor H-Related Protein 5. J Immunol 2021:ji2000072. [PMID: 34193601 DOI: 10.4049/jimmunol.2000072] [Reference Citation Analysis]
56 Ding Y, Zhao W, Zhang T, Qiang H, Lu J, Su X, Wen S, Xu F, Zhang M, Zhang H, Zeng C, Liu Z, Chen H. A haplotype in CFH family genes confers high risk of rare glomerular nephropathies. Sci Rep 2017;7:6004. [PMID: 28729648 DOI: 10.1038/s41598-017-05173-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
57 Reza MJ, Kamble A, Ahmad M, Krishnasastry MV, Sahu A. Dissection of functional sites in herpesvirus saimiri complement control protein homolog. J Virol 2013;87:282-95. [PMID: 23077301 DOI: 10.1128/JVI.01867-12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
58 Ferrara D, Seddon JM. Phenotypic Characterization of Complement Factor H R1210C Rare Genetic Variant in Age-Related Macular Degeneration. JAMA Ophthalmol 2015;133:785-91. [PMID: 25880396 DOI: 10.1001/jamaophthalmol.2015.0814] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
59 Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment. Mol Immunol 2017;84:65-76. [PMID: 27939104 DOI: 10.1016/j.molimm.2016.11.016] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 12.7] [Reference Citation Analysis]
60 Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 2019;34:1337-48. [PMID: 30109445 DOI: 10.1007/s00467-018-4039-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
61 Ferreira VP, Pangburn MK, Cortés C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol 2010;47:2187-97. [PMID: 20580090 DOI: 10.1016/j.molimm.2010.05.007] [Cited by in Crossref: 239] [Cited by in F6Publishing: 213] [Article Influence: 19.9] [Reference Citation Analysis]
62 Tati R, Kristoffersson AC, Ståhl AL, Rebetz J, Wang L, Licht C, Motto D, Karpman D. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol 2013;191:2184-93. [PMID: 23878316 DOI: 10.4049/jimmunol.1301221] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
63 Oppermann M, Manuelian T, Józsi M, Brandt E, Jokiranta TS, Heinen S, Meri S, Skerka C, Götze O, Zipfel PF. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol 2006;144:342-52. [PMID: 16634809 DOI: 10.1111/j.1365-2249.2006.03071.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 118] [Article Influence: 7.6] [Reference Citation Analysis]
64 Yeo NJY, Chan EJJ, Cheung C. Choroidal Neovascularization: Mechanisms of Endothelial Dysfunction. Front Pharmacol 2019;10:1363. [PMID: 31849644 DOI: 10.3389/fphar.2019.01363] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
65 Seddon JM, Yu Y, Miller EC, Reynolds R, Tan PL, Gowrisankar S, Goldstein JI, Triebwasser M, Anderson HE, Zerbib J, Kavanagh D, Souied E, Katsanis N, Daly MJ, Atkinson JP, Raychaudhuri S. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet 2013;45:1366-70. [PMID: 24036952 DOI: 10.1038/ng.2741] [Cited by in Crossref: 198] [Cited by in F6Publishing: 187] [Article Influence: 22.0] [Reference Citation Analysis]
66 Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 2019;26:99-110. [PMID: 30393246 DOI: 10.5551/jat.RV17026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
67 Bekassy Z, Lopatko Fagerström I, Bader M, Karpman D. Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. Nat Rev Immunol 2021. [PMID: 34759348 DOI: 10.1038/s41577-021-00634-8] [Reference Citation Analysis]
68 Densen P. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: emerging insights for vascular integrity. Curr Infect Dis Rep 2005;7:319-21. [PMID: 16107226 DOI: 10.1007/s11908-005-0002-4] [Reference Citation Analysis]
69 Goicoechea de Jorge E, Tortajada A, García SP, Gastoldi S, Merinero HM, García-Fernández J, Arjona E, Cao M, Remuzzi G, Noris M, Rodríguez de Córdoba S. Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018;29:240-9. [PMID: 28993505 DOI: 10.1681/ASN.2017050518] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
70 Boyer DS, Schmidt-Erfurth U, van Lookeren Campagne M, Henry EC, Brittain C. THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET. Retina 2017;37:819-35. [PMID: 27902638 DOI: 10.1097/IAE.0000000000001392] [Cited by in Crossref: 68] [Cited by in F6Publishing: 32] [Article Influence: 13.6] [Reference Citation Analysis]
71 Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Königsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke G, Zipfel PF. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 2003;40:676-81. [PMID: 12960213 DOI: 10.1136/jmg.40.9.676] [Cited by in Crossref: 153] [Cited by in F6Publishing: 147] [Article Influence: 8.1] [Reference Citation Analysis]
72 Bajic G, Degn SE, Thiel S, Andersen GR. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J 2015;34:2735-57. [PMID: 26489954 DOI: 10.15252/embj.201591881] [Cited by in Crossref: 165] [Cited by in F6Publishing: 149] [Article Influence: 23.6] [Reference Citation Analysis]
73 Schramm EC, Clark SJ, Triebwasser MP, Raychaudhuri S, Seddon J, Atkinson JP. Genetic variants in the complement system predisposing to age-related macular degeneration: a review. Mol Immunol 2014;61:118-25. [PMID: 25034031 DOI: 10.1016/j.molimm.2014.06.032] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 9.3] [Reference Citation Analysis]
74 Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27:2673-2685. [PMID: 22802583 DOI: 10.1093/ndt/gfs279] [Cited by in Crossref: 121] [Cited by in F6Publishing: 93] [Article Influence: 12.1] [Reference Citation Analysis]
75 Atkinson JP. Complement system on the attack in autoimmunity. J Clin Invest 2003;112:1639-41. [PMID: 14660739 DOI: 10.1172/JCI20309] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
76 Bu F, Maga T, Meyer NC, Wang K, Thomas CP, Nester CM, Smith RJ. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014;25:55-64. [PMID: 24029428 DOI: 10.1681/ASN.2013050453] [Cited by in Crossref: 144] [Cited by in F6Publishing: 65] [Article Influence: 16.0] [Reference Citation Analysis]
77 Martinez-Barricarte R, Pianetti G, Gautard R, Misselwitz J, Strain L, Fremeaux-Bacchi V, Skerka C, Zipfel PF, Goodship T, Noris M, Remuzzi G, de Cordoba SR; European Working Party on the Genetics of HUS. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2008;19:639-46. [PMID: 18235085 DOI: 10.1681/ASN.2007080923] [Cited by in Crossref: 67] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
78 Langford-Smith A, Keenan TD, Clark SJ, Bishop PN, Day AJ. The role of complement in age-related macular degeneration: heparan sulphate, a ZIP code for complement factor H? J Innate Immun 2014;6:407-16. [PMID: 24335201 DOI: 10.1159/000356513] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
79 Chaudhary P, Hepgur M, Sarkissian S, Smith RJ, Weitz IC. Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479. Blood Transfus 2014;12:111-3. [PMID: 24333077 DOI: 10.2450/2013.0107-13] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
80 Jokiranta TS. HUS and atypical HUS. Blood. 2017;129:2847-2856. [PMID: 28416508 DOI: 10.1182/blood-2016-11-709865] [Cited by in Crossref: 124] [Cited by in F6Publishing: 101] [Article Influence: 24.8] [Reference Citation Analysis]
81 Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-1279. [PMID: 16621965 DOI: 10.1182/blood-2005-10-007252] [Cited by in Crossref: 499] [Cited by in F6Publishing: 410] [Article Influence: 31.2] [Reference Citation Analysis]
82 Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:345-357. [PMID: 19625716 DOI: 10.1056/nejmoa0810739] [Cited by in Crossref: 368] [Cited by in F6Publishing: 153] [Article Influence: 28.3] [Reference Citation Analysis]
83 Tille A, Lehnert T, Zipfel PF, Figge MT. Quantification of Factor H Mediated Self vs. Non-self Discrimination by Mathematical Modeling. Front Immunol 2020;11:1911. [PMID: 33013842 DOI: 10.3389/fimmu.2020.01911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 de Córdoba SR, de Jorge EG. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 2008;151:1-13. [PMID: 18081690 DOI: 10.1111/j.1365-2249.2007.03552.x] [Cited by in Crossref: 192] [Cited by in F6Publishing: 184] [Article Influence: 13.7] [Reference Citation Analysis]
85 Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, López-Trascasa M, Sánchez-Corral P, Morgan BP, Rodríguez de Córdoba S. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA. 2007;104:240-245. [PMID: 17182750 DOI: 10.1073/pnas.0603420103] [Cited by in Crossref: 330] [Cited by in F6Publishing: 289] [Article Influence: 20.6] [Reference Citation Analysis]
86 Kerr H, Richards A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology 2012;217:195-203. [PMID: 21855165 DOI: 10.1016/j.imbio.2011.07.028] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
87 Wagner EK, Raychaudhuri S, Villalonga MB, Java A, Triebwasser MP, Daly MJ, Atkinson JP, Seddon JM. Mapping rare, deleterious mutations in Factor H: Association with early onset, drusen burden, and lower antigenic levels in familial AMD. Sci Rep 2016;6:31531. [PMID: 27572114 DOI: 10.1038/srep31531] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
88 Liszewski MK, Leung MK, Schraml B, Goodship TH, Atkinson JP. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol 2007;44:1559-68. [PMID: 17027083 DOI: 10.1016/j.molimm.2006.08.024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
89 Zhan X, Larson DE, Wang C, Koboldt DC, Sergeev YV, Fulton RS, Fulton LL, Fronick CC, Branham KE, Bragg-Gresham J, Jun G, Hu Y, Kang HM, Liu D, Othman M, Brooks M, Ratnapriya R, Boleda A, Grassmann F, von Strachwitz C, Olson LM, Buitendijk GH, Hofman A, van Duijn CM, Cipriani V, Moore AT, Shahid H, Jiang Y, Conley YP, Morgan DJ, Kim IK, Johnson MP, Cantsilieris S, Richardson AJ, Guymer RH, Luo H, Ouyang H, Licht C, Pluthero FG, Zhang MM, Zhang K, Baird PN, Blangero J, Klein ML, Farrer LA, DeAngelis MM, Weeks DE, Gorin MB, Yates JR, Klaver CC, Pericak-Vance MA, Haines JL, Weber BH, Wilson RK, Heckenlively JR, Chew EY, Stambolian D, Mardis ER, Swaroop A, Abecasis GR. Identification of a rare coding variant in complement 3 associated with age-related macular degeneration. Nat Genet 2013;45:1375-9. [PMID: 24036949 DOI: 10.1038/ng.2758] [Cited by in Crossref: 115] [Cited by in F6Publishing: 99] [Article Influence: 12.8] [Reference Citation Analysis]
90 Andrighetto S, Leventhal J, Zaza G, Cravedi P. Complement and Complement Targeting Therapies in Glomerular Diseases. Int J Mol Sci 2019;20:E6336. [PMID: 31888179 DOI: 10.3390/ijms20246336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
91 Lorenzen JM, Menne J, Schmidt BM, Schmidt M, Martino F, Dietrich R, Samiri S, Worthmann H, Heeren M, Weissenborn K, Haller H, Schiffer M, Kielstein JT, Thum T. Circulating microRNAs in patients with Shiga-Toxin-producing E. coli O104:H4 induced hemolytic uremic syndrome. PLoS One 2012;7:e47215. [PMID: 23071762 DOI: 10.1371/journal.pone.0047215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
92 Filler G, Radhakrishnan S, Strain L, Hill A, Knoll G, Goodship TH. Challenges in the management of infantile factor H associated hemolytic uremic syndrome. Pediatr Nephrol 2004;19:908-11. [PMID: 15206027 DOI: 10.1007/s00467-004-1526-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.1] [Reference Citation Analysis]
93 Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 2015;14:857-77. [PMID: 26493766 DOI: 10.1038/nrd4657] [Cited by in Crossref: 227] [Cited by in F6Publishing: 210] [Article Influence: 32.4] [Reference Citation Analysis]
94 Raychaudhuri S, Iartchouk O, Chin K, Tan PL, Tai AK, Ripke S, Gowrisankar S, Vemuri S, Montgomery K, Yu Y, Reynolds R, Zack DJ, Campochiaro B, Campochiaro P, Katsanis N, Daly MJ, Seddon JM. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet 2011;43:1232-6. [PMID: 22019782 DOI: 10.1038/ng.976] [Cited by in Crossref: 209] [Cited by in F6Publishing: 203] [Article Influence: 19.0] [Reference Citation Analysis]
95 Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V. Inherited Kidney Complement Diseases. Clin J Am Soc Nephrol 2021;16:942-56. [PMID: 33536243 DOI: 10.2215/CJN.11830720] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Berger SP, Daha MR. Complement in glomerular injury. Semin Immunopathol 2007;29:375-84. [PMID: 17901956 DOI: 10.1007/s00281-007-0090-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
97 Zipfel PF, Wiech T, Stea ED, Skerka C. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Am Soc Nephrol 2020;31:241-56. [PMID: 31980588 DOI: 10.1681/ASN.2019050515] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
98 Menon MC, Chuang PY, He CJ. The glomerular filtration barrier: components and crosstalk. Int J Nephrol. 2012;2012:749010. [PMID: 22934182 DOI: 10.1155/2012/749010] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
99 Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141 [PMID: 30211021 DOI: 10.5500/wjt.v8.i5.122] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
100 Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 2005;9:183-91. [PMID: 16189625 DOI: 10.1007/s10157-005-0357-8] [Cited by in Crossref: 109] [Cited by in F6Publishing: 91] [Article Influence: 6.4] [Reference Citation Analysis]
101 Park HJ, Atkinson JP. Autoimmunity: homeostasis of innate immunity gone awry. J Clin Immunol 2012;32:1148-52. [PMID: 23054347 DOI: 10.1007/s10875-012-9815-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
102 Martínez-Barricarte R, Goicoechea de Jorge E, Montes T, Layana AG, Rodríguez de Córdoba S. Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population. Clin Exp Immunol 2009;155:59-64. [PMID: 19076829 DOI: 10.1111/j.1365-2249.2008.03798.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
103 Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57. [PMID: 20556434 DOI: 10.1007/s00467-010-1556-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
104 Poppelaars F, Faria B, Schwaeble W, Daha MR. The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases? J Clin Med 2021;10:4715. [PMID: 34682837 DOI: 10.3390/jcm10204715] [Reference Citation Analysis]
105 Shaughnessy J, Ram S, Bhattacharjee A, Pedrosa J, Tran C, Horvath G, Monks B, Visintin A, Jokiranta TS, Rice PA. Molecular characterization of the interaction between sialylated Neisseria gonorrhoeae and factor H. J Biol Chem 2011;286:22235-42. [PMID: 21531728 DOI: 10.1074/jbc.M111.225516] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
106 Xu B, Kang Y, Du Y, Guo W, Zhu L, Zhang H. Atypical Hemolytic Uremic Syndrome-Associated FHR1 Isoform FHR1*B Enhances Complement Activation and Inflammation. Front Immunol 2022;13:755694. [DOI: 10.3389/fimmu.2022.755694] [Reference Citation Analysis]
107 Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009;9:729-740. [PMID: 19730437 DOI: 10.1038/nri2620] [Cited by in Crossref: 780] [Cited by in F6Publishing: 720] [Article Influence: 60.0] [Reference Citation Analysis]
108 Lorés-Motta L, van Beek AE, Willems E, Zandstra J, van Mierlo G, Einhaus A, Mary JL, Stucki C, Bakker B, Hoyng CB, Fauser S, Clark SJ, de Jonge MI, Nogoceke E, Koertvely E, Jongerius I, Kuijpers TW, den Hollander AI. Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration. Am J Hum Genet 2021;108:1367-84. [PMID: 34260947 DOI: 10.1016/j.ajhg.2021.06.002] [Reference Citation Analysis]
109 Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124:1715-1726. [PMID: 25037630 DOI: 10.1182/blood-2014-02-558296] [Cited by in Crossref: 189] [Cited by in F6Publishing: 171] [Article Influence: 23.6] [Reference Citation Analysis]
110 Davin JC, Strain L, Goodship TH. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol 2008;23:1517-21. [PMID: 18483746 DOI: 10.1007/s00467-008-0833-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
111 Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, Provôt F, Brocklebank V, Mele C, Remuzzi G, Loirat C, Frémeaux-Bacchi V, Fakhouri F. Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clin J Am Soc Nephrol 2017;12:1237-47. [PMID: 28596415 DOI: 10.2215/CJN.00280117] [Cited by in Crossref: 86] [Cited by in F6Publishing: 37] [Article Influence: 17.2] [Reference Citation Analysis]
112 Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508-530. [PMID: 24161037 DOI: 10.1016/j.semnephrol.2013.08.003] [Cited by in Crossref: 204] [Cited by in F6Publishing: 156] [Article Influence: 25.5] [Reference Citation Analysis]
113 Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement System Part II: Role in Immunity. Front Immunol 2015;6:257. [PMID: 26074922 DOI: 10.3389/fimmu.2015.00257] [Cited by in Crossref: 353] [Cited by in F6Publishing: 385] [Article Influence: 50.4] [Reference Citation Analysis]
114 Barratt J, Weitz I. Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway. Front Immunol 2021;12:712572. [PMID: 34566967 DOI: 10.3389/fimmu.2021.712572] [Reference Citation Analysis]
115 Hyvärinen S, Jokiranta TS. Minor Role of Plasminogen in Complement Activation on Cell Surfaces. PLoS One 2015;10:e0143707. [PMID: 26637181 DOI: 10.1371/journal.pone.0143707] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
116 Kouser L, Abdul-Aziz M, Nayak A, Stover CM, Sim RB, Kishore U. Properdin and factor h: opposing players on the alternative complement pathway “see-saw”. Front Immunol. 2013;4:93. [PMID: 23630525 DOI: 10.3389/fimmu.2013.00093] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
117 Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ. New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep 2014;34:e00146. [PMID: 25188723 DOI: 10.1042/BSR20140117] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 5.9] [Reference Citation Analysis]
118 Kajander T, Lehtinen MJ, Hyvärinen S, Bhattacharjee A, Leung E, Isenman DE, Meri S, Goldman A, Jokiranta TS. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A 2011;108:2897-902. [PMID: 21285368 DOI: 10.1073/pnas.1017087108] [Cited by in Crossref: 171] [Cited by in F6Publishing: 156] [Article Influence: 15.5] [Reference Citation Analysis]
119 Muff-Luett M, Nester CM. The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet 2016;5:33-42. [PMID: 27617140 DOI: 10.1055/s-0036-1572515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]